Thursday, 15 October 2026European Markets

European Currency Markets

5 articles

Sterling Falls to $1.3086 as UK Budget Fears Drive Safe-Haven Flows to Swiss Franc

Sterling Falls to $1.3086 as UK Budget Fears Drive Safe-Haven Flows to Swiss Franc

The pound dropped 0.5% against the dollar to $1.3086 and fell 0.4% to €1.13, its lowest level since April 2023, as investors shifted to Swiss franc safe havens ahead of the UK budget on November 26. UK 30-year gilt yields climbed to 5.21%, the highest since 1998, while the broader dollar weakness that lifted sterling 7% in 2025 now reverses.

ViaNews Editorial Team (Europe)•
Euro Surges 14% Against Dollar, Strongest Performance Since 2022

Euro Surges 14% Against Dollar, Strongest Performance Since 2022

The Euro has gained 14% against the U.S. dollar in 2025, reaching its highest level since 2022 as broad-based dollar weakness reshapes currency markets. European exporters stand to benefit from improved competitiveness, while carry trade opportunities emerge for European investors amid global monetary policy shifts.

ViaNews Editorial Team (Europe)•
Euro Gains Ground as Dollar Index Recovers from 2022 Lows Amid Fed Chair Transition

Euro Gains Ground as Dollar Index Recovers from 2022 Lows Amid Fed Chair Transition

The Bloomberg Dollar Spot Index rebounded modestly after hitting its lowest level since 2022, pressuring the euro and pound in volatile trading. The British pound faces additional headwinds ahead of the UK Budget on November 26, while the euro adjusts to dollar movements amid uncertainty over the Federal Reserve leadership transition scheduled for June 2026.

ViaNews Editorial Team (Europe)•
Euro Surges 14% Against Dollar as US Currency Hits 2022 Lows

Euro Surges 14% Against Dollar as US Currency Hits 2022 Lows

The euro has gained 14% against the US dollar in 2025, while the British pound climbed 7%, as the greenback fell to its lowest level since 2022. The dollar's weakness stems from uncertainty ahead of Jerome Powell's June 2026 Federal Reserve departure and shifting investor sentiment toward European currencies.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com